CircRNA Biomarkers for Heart Failure Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarkers for predicting heart failure after myocardial infarction lack specificity and stability, making it challenging to accurately diagnose and manage patients at risk of left ventricular dysfunction.
Innovation Solution
The use of myocardial infarction-associated circular RNAs (circRNAs), such as ZNF609_hsa_circ_0000615 (MICRA), as new biomarkers for diagnosing and predicting heart failure by determining their expression levels in patient samples, combined with clinical factors and other biomarkers, to assess the likelihood of developing heart failure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional biomarkers (CPK, cTn, BNP) are used for predicting heart failure after myocardial infarction, then the diagnostic capability is provided, but the specificity and stability are insufficient
Solution Approach 1:
The patent changes the molecular parameter being measured from traditional proteins (CPK, cTn, BNP) to circular RNAs (specifically hsa_circ_0000615 and other circRNAs listed in Table 1). This parameter change enables both high diagnostic capability and improved specificity/stability, as circRNAs are more stable in biological fluids and show better predictive performance for heart failure after MI.
2Measurement precision
If novel biomarkers are developed to improve prediction accuracy, then the diagnostic precision is enhanced, but the complexity of detection and analysis increases
Solution Approach 1:
The patent uses RT-PCR to convert RNA molecules into DNA copies, which can then be amplified and detected using standard molecular biology techniques. This copying approach allows for precise measurement of circRNA expression levels while using well-established, relatively simple detection methods rather than requiring complex new technologies.
Data Source
Figure 1A~1B
Figure 2A~2C
Figure 3A~3D
AI summary
The application discloses circRNAs as new biomarkers for the development of heart failure after myocardial infarction; methods for the prediction and diagnosis of heart failure are provided based on measuring said one or more circRNAs; and kits and devices for measuring said circRNAs and/or performing said methods. Further provided are methods for treating patients at risk of heart failure based on the evaluation of said one or more circRNAs.